Teva Canada Welcomes Efforts to Address Critical Drug Supply in the Federal Budget
News provided by
Share this article
Share this article
TORONTO, April 20, 2021 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., strongly welcomes the Government of Canada s commitment in the April 19, 2021 federal budget to support Canada s life science sector. The Budget includes $2.2 billion over seven years towards growing a vibrant domestic life sciences sector and will be part of the plan to build domestic resilience and improve long-term pandemic preparedness .
Christine Poulin, General Manager of Teva Canada, said the organization is encouraged that the federal government is promoting long-term sustainable growth in Canada s biomanufacturing sector. She made the following statement:
Teva Canada Amplifies Commitment to Canadian Caregivers - Introduces new resources to support and improve mental health of Caregivers newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Teva to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 7, 2021 GMT
TEL AVIV, Israel (BUSINESS WIRE) Jan 7, 2021
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 13, 2021. The presentation will begin at 8:20 A.M. Eastern Time.
To access a live webcast of the presentation, visit Teva’s Investor Relations website at http://ir.tevapharm.com.
ADVERTISEMENT
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
Regulatory News:
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the RISE study The Risperidone Subcutaneous Extended-Release Study), a Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) as a treatment for patients with schizophrenia. Trial enrollment was open to patients 13-65 years of age. In the RISE study, patients treated with the investigational subcutaneous risperidone injection either monthly (q1M) (n=183) or once every two months (q2M) (n=179) experienced a statistically significant delay in time to relapse versus placebo (n=181), the study s primary endpoint, with p